News
Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic versions of its blockbuster blood cancer drug Pomalyst off the market so it could ...
13d
Zacks Investment Research on MSNWill The Decline in Legacy Drugs Pull Down BMY's Top Line?Bristol Myers’ BMY legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane. Revenues for the Legacy ...
Pomalyst is a prescription drug used to treat multiple myeloma and Kaposi sarcoma. Learn about the drug’s dosages, form, strengths, and more.
Celgene announced that the FDA has approved Pomalyst (pomalidomide) for the treatment of patients with relapsed and/or refractory multiple myeloma.
Celgene's Pomalyst takes the stage in a pharma-style family tradition. Its parent has one of the longest and varied histories in the annals of medicine. Its sibling is a star raking in billions of ...
Looking ahead Otezla's and Pomalyst's success have only strengthened Celgene's reputation as one of the industry's best developers of increasingly effective, top-selling medicine.
Pomalyst and Abraxane are the next largest revenue generators for Celgene (CELG) after Revlimid. Their revenue growth is critical for Celgene to achieve revenues of $20 billion by 2020.
Pomalyst appears to be on track to eventually hit annual sales between $1 billion and $2 billion. If that happens, the drug would by far eclipse the success of Thalomid.
Already approved as a second-line multiple myeloma therapy, Revlimid was approved as a first-line therapy for newly diagnosed patients by the FDA in February.
Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse payments to delay cheaper generics of Pomalyst.
In 2022, Pomalyst generated nearly $3.5 billion (₹30,000 crore) in revenue, marking a 5% increase from the previous year. See Also: Viacom18 Scores Big Again Bagging Exclusive ISL Broadcasting ...
Pomalyst plus Velcade with dexamethasone improves survival outcomes for patients with relapsed/refractory multiple myeloma, according to a phase 3 trial.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results